Videos
Next generation anticancer approaches: Innovation meets commercial realitiesMarch 20, 2012 | BIO-Europe Spring® 2012This discussion focuses on how commercial realities meet innovation within oncology, covering challenges companies face as oncology becomes increasingly competitive. view "full session" 
The assessment and management of assets: How to position the asset to attract a dealMarch 20, 2012 | BIO-Europe Spring® 2012There is still a great deal to learn about how to better position an asset to attract investors or deal partners, with an understanding of both short and long term goals.view "full session" 
Biotech business models for faster returnsMarch 19, 2012 | BIO-Europe Spring® 2012Nimble entrepreneurs are developing funds and corporate structures that may once again make private biotech an attractive investment, focusing on the drug, not the company.view "full session" 
Close up and personal: Recent deals examined from both sidesMarch 19, 2012 | BIO-Europe Spring® 2012With special emphasis on Dutch biotech deals, executives discuss what the dealmaking hurdles were, what they learned from the process, and how the alliance has been managedview "full session" 
Regional focus: Leveraging commercial rights for emerging marketsMarch 19, 2012 | BIO-Europe Spring® 2012Life science companies are shifting focus to take advantage of specialty indications and regional markets, such as China, the Middle East, Russia and South Americaview "full session" 
Early stage financing: European and US VCs weigh inMarch 19, 2012 | BIO-Europe Spring® 2012Is there a recipe for current VCs for successful investing in early stage science? Will recent initiatives from both government and industry help or hurt the venture industry?view "full session" 
Advanced therapies: Stem cell and immunotherapy promises in practiceMarch 19, 2012 | BIO-Europe Spring® 2012This panel examines major clinical and commercial developments in using stem cells as drug discovery platforms, as well as the development of immunotherapies to treat cancer.view "full session" 
Unconventional deals to herculean strategiesMarch 19, 2012 | BIO-Europe Spring® 2012New realities in healthcare have caused investors to lean toward non-traditional dealmaking strategies. Panelists explore multifaceted, powerful, even herculean, strategies.view "full session" 
The opportunity of community drug development partnerships for personalized oncology and drug developmentMarch 19, 2012 | BIO-Europe Spring® 2012Will community drug development partnerships among academic institutions, diagnostics companies, technology providers and bio/pharma lead to more effective cancer drugs?view "full session" 
Are orphan indications the only viable model for drug development?March 19, 2012 | BIO-Europe Spring® 2012The opening plenary addresses orphan indications as a viable model for drug development. Panelists discuss development strategies and the future of personalized medicine.view "full session" 
Examining major deals of the past yearMarch 19, 2012 | BIO-Europe Spring® 2012Panelists examine significant deals of 2011, including what these deals reveal about pharma’s priorities, strategy and the options available to drug development companies.view "full session"
© 2009–2012 EBD Group AG
